{"name":"Danaher","slug":"danaher","ticker":"DHR","exchange":"NYSE","domain":"danaher.com","description":"Danaher is a surname. Notable people with the surname include:Declan Danaher, English Rugby union player\nJody Danaher, Irish rugby player\nJohn Danaher, New Zealand Brazilian jiu-jitsu and mixed martial arts instructor\nJohn Danaher (VC) (1860–1919), Irish recipient of the Victoria Cross\nJohn A. Danaher (1899–1990), American politician and judge\nJohn A. Danaher III, grandson of the above, commissioner of the Connecticut Department of Public Safety\nKevin Danaher, (1913–2002), Irish author and folklorist\nKevin Danaher (activist), American author and anti-globalization activist\nPhil Danaher, American football coach\nPhil Danaher, Irish rugby player\nPhyllis Danaher (1908–1991), Australian dancer, teacher of dance, and choreographer","hq":"Washington, D.C., USA","founded":0,"employees":"58000","ceo":"Rainer M. Blair","sector":"Life Science Tools / Diagnostics","stockPrice":166.13,"stockChange":0.14,"stockChangePercent":0.08,"marketCap":"$117.6B","metrics":{"revenue":24778000384,"revenueGrowth":3.7,"grossMargin":59,"rdSpend":1598000000,"netIncome":3614000000,"cash":5701000192,"dividendYield":0.96,"peRatio":32.2,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"LeukoScan patent cliff ($100M at risk)","drug":"LeukoScan","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-01","type":"earnings","headline":"Danaher Reports Fourth Quarter and Full Year 2023 Results","summary":"Danaher reported fourth quarter and full year 2023 results, with revenue of $7.4 billion and adjusted EPS of $2.33.","drugName":"","sentiment":"positive"},{"date":"2023-11-01","type":"deal","headline":"Danaher to Acquire Aldevron","summary":"Danaher announced the acquisition of Aldevron, a leading provider of plasmid DNA and mRNA for the biotechnology and pharmaceutical industries.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"FDA Approves Danaher's LeukoScan","summary":"The FDA approved LeukoScan, a diagnostic imaging agent for the detection of bone and soft tissue infections.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-07","type":"pipeline","source":"simplywall.st","summary":"Evaluating Danaher (DHR) After Mixed Recent Returns And Conflicting Undervaluation Signals - simplywall.st","headline":"Evaluating Danaher (DHR) After Mixed Recent Returns And Conflicting Undervaluation Signals","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-28","type":"pipeline","source":"simplywall.st","summary":"A Look At Danaher (DHR) Valuation After Recent Share Price Weakness - simplywall.st","headline":"A Look At Danaher (DHR) Valuation After Recent Share Price Weakness","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-25","type":"pipeline","source":"simplywall.st","summary":"Is It Time To Reassess Danaher (DHR) After Recent Share Price Weakness? - simplywall.st","headline":"Is It Time To Reassess Danaher (DHR) After Recent Share Price Weakness?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNeDFDRVFPM2dBUmxIdFBjNGt5aVU2OVlKQzItbjMweEZ4TGVqRGE0bXhYV1AwQTFtcFRLamhPVUM3N2lrVVRJcFJwQjBueXBxRDNBV2xCOGFaWUpfQmFYVWNGR3NkeF9EN1FNVER5dXpVZzFEYmM1VmJHelo3djBOaFhwX05MZk80V3dybWtGZm9DOGFvLTlCQzNoOHhpdVpEVktrZkVES2YwWjFRSkNBTnotc3EzQklIOWlIYkZ2eTVnMXpzclE?oc=5","date":"2026-02-17","type":"deal","source":"reuters.com","summary":"Danaher closes in on nearly $10 billion deal for Masimo, FT reports - reuters.com","headline":"Danaher closes in on nearly $10 billion deal for Masimo, FT reports","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQeXFROUk2cUZfUE53MXJNZTl0QmFLbnY2MnNYUjBZWjNHWkN4WG5vZnZzc0dFV1d1eFBGaTZuSUc0VEZFRmM1ZjFqNWZpNlROdTFmMTRpRG03dGcwRzBPeENCbnVUOEVrMTBpUS1INU1nM0VwT2txbFFabkViOWw1QWlXclllOEhlUHVRZjJ2cWd3ZnhsTFdxTk00cU9vNFplR01RZlNtRFRRLXE3YUJiQVYxV184UlNpLUE?oc=5","date":"2026-02-17","type":"deal","source":"proactiveinvestors.com","summary":"Danaher to acquire Masimo in $9.9B all-cash deal - proactiveinvestors.com","headline":"Danaher to acquire Masimo in $9.9B all-cash deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPUG8tdGQwOEpJSWU3UkZBU2NncXRxZVIwS2ZtUkFGM0duT0d1VVNwRFFhTWxJb2hTSXhoWV9pTDlncHVrWU5hV1k0ZVI0enhKTjkyWmFYdWRDZV9PZXJwWXlMbUZHTWNUOFNJY2Y5YWpvZEVSYmZvdjNURlZwQWRXQmV0LW9PNGdUMUYzeEJCeE5wWjA?oc=5","date":"2026-02-17","type":"deal","source":"PharmaLive","summary":"Danaher to buy Masimo in $9.9 billion deal in diagnostics push - PharmaLive","headline":"Danaher to buy Masimo in $9.9 billion deal in diagnostics push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPOFVoRlgtY3NEcDB0X203M1JpR1A3NmE1TnEwbUtlbmxQOGFPb1hfOWRleVgxSkkzeHF0U1NkdG9tczdyWEV3LURsVFdXSUxPeU1ESmdGeHBKV3dZWEhvXzVPMGNEQjVaR2lEaFpZc29GVWNHM2Y2Rkg4NnNYTGIzRF9hUzVPZUIwXzUzVUdXZjVqUzdCWkZBOXZtUnNWbmFXZ1lr?oc=5","date":"2026-02-17","type":"deal","source":"reuters.com","summary":"Danaher to buy Masimo in $9.9 billion deal in diagnostics push - reuters.com","headline":"Danaher to buy Masimo in $9.9 billion deal in diagnostics push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQWHBXT0xWcDlIUS1NdVZSZ0ZINi1sVC1zLWpCZ09EbzhRcjk0RFloVnplX0RVYTIxeDNUTEhXUkJDd2hfU2NldGFDY0hYNTBKS2FJR0NMUkZtcDlob2FVYnRaclVvU1BWTmZKZW1rc0Ytd0kzX1Y4NHBuSFRqYzNiMFNjZnJSc2h0YWpoVFVMNjN4NHFOZ0dfbjhPengtdHNteWszZ1YxamFjc3VCdURjTGxmNk1lT1NmVGtxYw?oc=5","date":"2026-02-03","type":"earnings","source":"TradingView","summary":"The Top 5 Analyst Questions From Danaher’s Q4 Earnings Call - TradingView","headline":"The Top 5 Analyst Questions From Danaher’s Q4 Earnings Call","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOQUoyMUNvYURlV0dpN0RlWms4aXU1VUlwb1JJbFVrdHFWRVc4ZWVGZk1faGMyTWd6MzBIYndadlNxZkhSZHo1V0FpZHluY1lPYXFTWFI3ZHBMemNMSndCQTI1TENtMGlZazlOa0FMaWhZS3c2Y1VWa2JCeVNfaHFzaDNXbEVxaW9FRVNrSi1UbDJNWVZBQVFKVlRpTGhERm8?oc=5","date":"2026-01-29","type":"pipeline","source":"TechStock²","summary":"Danaher stock slides again after outlook: what DHR investors are watching next - TechStock²","headline":"Danaher stock slides again after outlook: what DHR investors are watching next - TechStock²","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxOZFI3cnVRTjdKT3NKRktlRlFYSU1NbXp1TWd3T2NqNXNoZmVOUXlFR0RmbU5SazR4QV9GaFNFNmxuaUhxNGpKSldlSG5meDBSQlkxWjRPdENlbVBIZnZxQWg2SXVZWXd2b0p6QnNuLTFqRUVFTnNGRzVEcjdUZnZkaF9zN29xeGYxZkhxUEFLS1JDMWp4Z1QycU9ZeXNlVWtrTG8wWkNuUTdTbFlzZ3NOaDlMSVN0LWxYR3lDdGU2aWtaQUd4RDJTUnNXOUxsYWdJX2lSU0g2OWxBSTQwZkRRT2pfZzQ2aUhhNUM3ajlycGV5d0YtR1hXWTUtTkhyeXNUcElkeHZXMEt3bUxtbkxydTdQbmMteFU?oc=5","date":"2025-12-02","type":"regulatory","source":"24/7 Wall St.","summary":"Here Are Tuesday's Top Wall Street Analyst Research Calls: Albemarle, Circle Internet, Cloudflare, Danaher, Inspire Medical, Six Flags, Workday and More - 24/7 Wall St.","headline":"Here Are Tuesday's Top Wall Street Analyst Research Calls: Albemarle, Circle Internet, Cloudflare, Danaher, Inspire Medi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxORGZyTjZRdmNXNld1WXJ0ak9JWEUyZDFfcVEtV2M5bTNEQmxKeGR2VzZ4TEZCdGI4Mm9IS0xSMElTSE14Zm05ekEyaFZ2aVhRcU80Tk1ia0dkb1RMcFE4NDJLQ1poUHp4djZjZHNocDltQTUyUTFKcDZza29LZ3pvcV9BTXVudw?oc=5","date":"2025-10-01","type":"pipeline","source":"Yahoo Finance","summary":"Danaher (DHR) Surges as Pharma Tariffs to Benefit Firm - Yahoo Finance","headline":"Danaher (DHR) Surges as Pharma Tariffs to Benefit Firm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOaWJ0SEF3QXBPTk5CVWVVU3Q0Z3hrZzhxei1UVVluVDBzZWl4TkFGMUx3MlNNMHpWNUtYaC1SSFYyZHhmeFJOeHB4TjZZSFoyeDVDRzlycEdEUDRhVzBZOWctaVdEWTRRdi1abEUzaTZpdFhlVk1EUXh3Vk4xQUlTSEh1RzRjQ0RaZHZRTDcwSmdJMVgwTUFGQ0czUmlsTkE?oc=5","date":"2025-06-19","type":"pipeline","source":"Seeking Alpha","summary":"Danaher: High Capex And Low Debt Despite Trump Legislation (NYSE:DHR) - Seeking Alpha","headline":"Danaher: High Capex And Low Debt Despite Trump Legislation (NYSE:DHR)","sentiment":"neutral"}],"patents":[{"drugName":"LeukoScan","drugSlug":"leukoscan","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Thermo Fisher Scientific","Agilent Technologies","PerkinElmer"],"therapeuticFocus":["Oncology","Infectious Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":19893000000,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":19893000000,"period":"2018-12-31"},{"value":5363500000,"period":"2018-12-31"},{"value":4853100000,"period":"2018-09-28"},{"value":4981000000,"period":"2018-06-29"},{"value":4695400000,"period":"2018-03-30"}],"grossProfit":14523000000,"grossProfitHistory":[{"period":"2025-12-31","value":14523000000},{"period":"2024-12-31","value":14206000000},{"period":"2023-12-31","value":14034000000},{"period":"2022-12-31","value":16188000000}],"rdSpend":1598000000,"rdSpendHistory":[{"period":"2025-12-31","value":1598000000},{"period":"2024-12-31","value":1584000000},{"period":"2023-12-31","value":1503000000},{"period":"2022-12-31","value":1528000000}],"sgaSpend":8235000000,"operatingIncome":4690000000,"operatingIncomeHistory":[{"period":"2025-12-31","value":4690000000},{"period":"2024-12-31","value":4863000000},{"period":"2023-12-31","value":5202000000},{"period":"2022-12-31","value":7536000000}],"netIncome":3614000000,"netIncomeHistory":[{"period":"2025-12-31","value":3614000000},{"period":"2024-12-31","value":3899000000},{"period":"2023-12-31","value":4764000000},{"period":"2022-12-31","value":7209000000}],"eps":5.05,"epsHistory":[{"period":"2025-12-31","value":5.05},{"period":"2024-12-31","value":5.29},{"period":"2023-12-31","value":6.38},{"period":"2022-12-31","value":9.66}],"cash":4615000000,"cashHistory":[{"period":"2025-12-31","value":4615000000},{"period":"2024-12-31","value":2078000000},{"period":"2023-12-31","value":5864000000},{"period":"2022-12-31","value":5995000000}],"totalAssets":83464000000,"totalLiabilities":30923000000,"totalDebt":19696000000,"equity":52534000000,"operatingCashflow":6416000000,"operatingCashflowHistory":[{"period":"2025-12-31","value":6416000000},{"period":"2024-12-31","value":6688000000},{"period":"2023-12-31","value":7164000000},{"period":"2022-12-31","value":8519000000}],"capex":-1156000000,"capexHistory":[{"period":"2025-12-31","value":-1156000000},{"period":"2024-12-31","value":-1392000000},{"period":"2023-12-31","value":-1383000000},{"period":"2022-12-31","value":-1118000000}],"freeCashflow":5260000000,"dividendsPaid":-878000000,"buybacks":-3088000000,"employees":58000,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":1860000000,"ebit":1298000000,"ebitda":1925000000,"period":"2026-03-31","revenue":5951000000,"epsBasic":1.45,"netIncome":1029000000,"rdExpense":387000000,"epsDiluted":1.45,"grossProfit":3591000000,"operatingIncome":1344000000},{"sga":2026000000,"ebit":1428000000,"ebitda":2051000000,"period":"2025-12-31","revenue":6838000000,"epsBasic":1.69,"netIncome":1197000000,"rdExpense":438000000,"epsDiluted":1.68,"grossProfit":3966000000,"operatingIncome":1502000000},{"sga":1991000000,"ebit":1143000000,"ebitda":1765000000,"period":"2025-09-30","revenue":6053000000,"epsBasic":1.28,"netIncome":908000000,"rdExpense":378000000,"epsDiluted":1.27,"grossProfit":3523000000,"operatingIncome":1154000000},{"sga":2360000000,"ebit":726000000,"ebitda":1337000000,"period":"2025-06-30","revenue":5936000000,"epsBasic":0.77,"netIncome":555000000,"rdExpense":403000000,"epsDiluted":0.77,"grossProfit":3523000000,"operatingIncome":760000000},{"sga":1858000000,"ebit":1201000000,"ebitda":1792000000,"period":"2025-03-31","revenue":5741000000,"epsBasic":1.33,"netIncome":954000000,"rdExpense":379000000,"epsDiluted":1.32,"grossProfit":3511000000,"operatingIncome":1274000000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":166.13,"previousClose":165.99,"fiftyTwoWeekHigh":242.8,"fiftyTwoWeekLow":163.32,"fiftyTwoWeekRange":"163.32 - 242.8","fiftyDayAverage":186.99,"twoHundredDayAverage":207.68,"beta":0.84,"enterpriseValue":131473850368,"forwardPE":18.3,"priceToBook":2.22,"priceToSales":4.75,"enterpriseToRevenue":5.31,"enterpriseToEbitda":16.57,"pegRatio":1.09,"ebitda":7935000064,"ebitdaMargin":32,"freeCashflow":4568500224,"operatingCashflow":6439000064,"totalDebt":19683999744,"debtToEquity":37.2,"currentRatio":1.87,"returnOnAssets":4.2,"returnOnEquity":7.1,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":22,"targetMeanPrice":250,"targetHighPrice":310,"targetLowPrice":205,"dividendRate":1.6,"payoutRatio":0.26,"fiveYearAvgDividendYield":0.43,"exDividendDate":1782432000,"insiderHeldPercent":10.7,"institutionHeldPercent":83.3,"sharesOutstanding":707770627,"floatShares":630659017,"sharesShort":8585579,"shortRatio":1.87,"shortPercentOfFloat":1.2,"epsTrailing":5.16,"epsForward":9.1,"revenuePerShare":34.87,"bookValue":74.82,"officers":[{"age":74,"name":"Mr. Steven M. Rales","title":"Co-Founder & Chairman"},{"age":61,"name":"Mr. Rainer M. Blair","title":"President, CEO & Director"},{"age":68,"name":"Mr. Mitchell P. Rales","title":"Co-Founder & Director"},{"age":63,"name":"Dr. Jose-Carlos  Gutierrez-Ramos Ph.D.","title":"Senior VP & Chief Science Officer"},{"age":53,"name":"Mr. Matthew R. McGrew","title":"Executive Vice President"},{"age":51,"name":"Mr. Christopher Paul Riley","title":"Executive VP of Biotechnology Group & CEO of Cytiva"},{"age":52,"name":"Ms. Julie Sawyer Montgomery","title":"Executive Vice President of Diagnostics Platform"},{"age":42,"name":"Mr. Matthew E. Gugino C.F.A., CPA","title":"Executive VP & CFO"}],"industry":"Diagnostics & Research","irWebsite":"http://phx.corporate-ir.net/phoenix.zhtml?c=82105&p=irol-irhome","website":"https://www.danaher.com","phone":"202 828 0850"}}